📇 Rhumatologue · PARIS CEDEX 14 · (75) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
14 articles scientifiques publiés — formation continue solide
Expérience confirmée
24 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
24ans d'exercice (thèse 2002)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Direction : José Timsit
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Screening for autoimmune atrophic gastritis by serum gastrin measurement in subjects with type 1 diabetes
2025ArticleDiabetes & Metabolism
PFMG2025–integrating genomic medicine into the national healthcare system in France
2025ArticleThe Lancet Regional Health - Europe
Pancreatic enzyme replacement therapy in subjects with exocrine pancreatic insufficiency and diabetes mellitus: a real-life, case–control study
2024ArticleDiabetology and Metabolic Syndrome
Pregnancy in Women With Monogenic Diabetes due to Pathogenic Variants of the Glucokinase Gene: Lessons and Challenges
2022ArticleFrontiers in Endocrinology
Validation in the general population of a C-peptide estimate equation to measure beta cell function in recent-onset type 1 diabetes
2021ArticleActa Diabetologica
Peptides Derived From Insulin Granule Proteins Are Targeted by CD8 + T Cells Across MHC Class I Restrictions in Humans and NOD Mice
2020ArticleDiabetes
Next-generation sequencing identifies monogenic diabetes in 16% of patients with late adolescence/adult-onset diabetes selected on a clinical basis: a cross-sectional analysis
2019ArticleBMC Medicine
Conventional and Neo-Antigenic Peptides Presented by β Cells Are Targeted by Circulating Naïve CD8+ T Cells in Type 1 Diabetic and Healthy Donors
2018ArticleCell Metabolism
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Annals of internal medicine · 2004
Diabetes care · 2004
OBJECTIVE—The reported rate of preterm delivery in women with type 1 diabetes ranges from 22 to 45%, but the reasons are unclear. The purpose of this study was to identify factors associated with preterm delivery in these women. RESEARCH DESIGN AND METHODS—We studied the influence of maternal and diabetes-related factors on the occurrence of preterm delivery in 168 single pregnancies occurring in 127 women with type 1 diabetes. Women with spontaneous or indicated preterm delivery were compared with those who delivered after 37 weeks of gestation using polytomous logistic regression. RESULTS—The overall rate of preterm delivery was 24%, fivefold higher than the French prematurity rate in single pregnancy. Preterm delivery was spontaneous in 9% and indicated in 15%. HbA1c ≥7% at delivery was associated with spontaneous preterm delivery (odds ratio [OR] 5.3 [95% CI 1.1–26.8]). Nulliparity (12.0 [2.3–64.1]), progression of nephropathy (7.7 [1.3–46.9]), preeclampsia (12.0 [3.1–47.1]), and HbA1c ≥7% (7.5 [1.5–37.9]) at delivery were all associated with indicated preterm delivery. Preterm delivery was associated with significant neonatal morbidity as the risks for neonatal hypoglycemia and respiratory distress syndrome were increased by three- to sixfold compared with the reference group. CONCLUSIONS—The rate of preterm delivery remains high in women with type 1 diabetes. Different factors were associated with spontaneous and indicated preterm delivery, respectively. Because poor glycemic control was a risk factor for both outcomes, part of preterm delivery might be preventable.
Clinical endocrinology · 2003
Summaryobjective A single nucleotide polymorphism (A1220G; N363S) in exon 2 of the glucocorticoid receptor gene (NR3C1), associated with increased sensitivity to glucocorticoids, was shown to be associated with obesity in nondiabetic subjects. Here, we investigated the impact of this variant on traits related to obesity and hyperglycaemia in subjects with type 2 diabetes mellitus.patients and measurements The N363S variant was screened by restriction fragment length polymorphism technique following DNA amplification by polymerase chain reaction in 369 French Caucasians with type 2 diabetes mellitus.results Twenty subjects were found to be heterozygous for the variant (AG genotype frequency 0·0542). The prevalence of overweight [body mass index (BMI) > 25 kg/m2] was higher in AG carriers than in AA carriers (100%vs. 73%, P = 0·003). Moreover, the mean body weight and the BMI were higher in AG as compared to AA carriers, although only the body weight was significantly different between groups. However, when only the men were considered, a significantly higher BMI was observed in AG as compared to AA carriers: 30·0 ± 4·8 vs. 27·3 ± 4·6 kg/m2 (BMI Z‐score 1·28 ± 1·38 vs. 0·55 ± 1·17; P = 0·035). No evidence was found for an association of the N363S variant with parameters related to the severity of hyperglycaemia.conclusions The 363S allele of the N363S variant of NR3C1 is associated with the susceptibility to overweight in subjects with type 2 diabetes mellitus.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Diabetology & metabolic syndrome · 2024 · Journal Article
Alexandre-Heymann L, Yaker F, Lassen PB, Dubois-Laforgue D, et al.
BMC medicine · 2019 · Journal Article
Donath X, Saint-Martin C, Dubois-Laforgue D, Rajasingham R, et al.
Diabetes · 2008 · Journal Article
Cheurfa N, Dubois-Laforgue D, Ferrarezi DA, Reis AF, et al.
Molecular genetics and metabolism · 2005 · Journal Article
Ghandil P, Chelala C, Dubois-Laforgue D, Senée V, et al.
Annals of internal medicine · 2004 · Journal Article
Bellanné-Chantelot C, Chauveau D, Gautier JF, Dubois-Laforgue D, et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2008 · Journal Article
Duchatelet S, Caillat-Zucman S, Dubois-Laforgue D, Blanc H, et al.
Molecular genetics and metabolism · 2004 · Journal Article
Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, Timsit J, et al.
Clinical endocrinology · 2003 · Journal Article
Roussel R, Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, et al.
Diabetes technology & therapeutics · 2023 · Multicenter Study
Diedisheim M, Pecquet C, Julla JB, Carlier A, et al.
Diabetes care · 2004 · Journal Article
Lepercq J, Coste J, Theau A, Dubois-Laforgue D, et al.
Diabetes, obesity & metabolism · 2025 · Journal Article
Vermillac G, Lafont C, Godot C, Kerbourc'h S, et al.
La Revue du praticien · 2003 · Journal Article
Timsit J, Dubois-Laforgue D
PloS one · 2014 · Journal Article
Li S, Joseph C, Becourt C, Klibi J, et al.
Clinical endocrinology · 2003 · Journal Article
Roussel R, Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, et al.
Diabetes technology & therapeutics · 2011 · Comparative Study
Renard E, Dubois-Laforgue D, Guerci B, Variability Study Group
✨ Profil synthétique
IA · 21/05/2026MME DANIELE DUBOIS-LAFORGUE est une rhumatologue hospitalière à Paris, avec une production scientifique significative dans le domaine du diabète et des troubles associés. Son h-index de 30 et ses 117 publications démontrent son engagement dans la recherche. Ses travaux couvrent également des aspects tels que la génétique, l'épidémiologie et les essais cliniques.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.